Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.53 |
| ▸ | RELA | Q04206 | 5/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078254 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL2137399 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL12951153 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4951462 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605621 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605148 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5270119 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605147 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL15215795 | 0.87 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL19337828 | 0.86 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448916-B1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | REDDYS LAB LTD DR (IN) | 2014-09-03 | — | — | EP | disclosed |
| US-8524943-B2 | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | DR. REDDY'S LABORATORIES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2011003061-A2 | PRODUCTION OF TRAN S-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-01-06 | — | — | WO | disclosed |
| EP-1763347-A4 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1763347-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1746997-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CZCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006004741-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005115392-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | NFKB1 2666/4885NFKB2 3295/4885RELA 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.